Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 6/20 | 0.45 |
| ▸ | SLC6A11 | P48066 | 6/20 | 0.45 |
| ▸ | SLC6A13 | Q9NSD5 | 6/20 | 0.45 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.45 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5957597 | 0.88 | — | — | |
| SCHEMBL7072429 | 0.85 | SLC6A12 (0.45) | SLC6A12SLC6A11SLC6A13SLC6A1GABRA5 | |
| SCHEMBL1493230 | 0.81 | ANPEP (0.56) | SLC6A12SLC6A11SLC6A13SLC6A1GABRA5 | |
| SCHEMBL74792 | 0.81 | — | — | |
| SCHEMBL431287 | 0.81 | ANPEP (0.56) | SLC6A12SLC6A11SLC6A13SLC6A1GABRA5 | |
| SCHEMBL24197646 | 0.81 | ANPEP (0.56) | SLC6A12SLC6A11SLC6A13SLC6A1GABRA5 | |
| SCHEMBL28300354 | 0.81 | ANPEP (0.56) | SLC6A12SLC6A11SLC6A13SLC6A1GABRA5 | |
| SCHEMBL24483431 | 0.81 | ANPEP (0.56) | SLC6A12SLC6A11SLC6A13SLC6A1GABRA5 | |
| Hydrochloric Acid SCHEMBL8681566 | 0.78 | — | — | |
| SCHEMBL15771317 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-06-23 | — | — | US | claimed |
| CN-110582493-A | Benzoxazole derivatives as immunomodulators | 因赛特公司 | 2019-12-17 | — | — | CN | claimed |
| EP-3558985-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | claimed |
| WO-2018119266-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | claimed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | claimed |
| JP-4796567-B2 | — | — | 2011-10-19 | — | — | JP | claimed |
| US-20100249114-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | claimed |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-17 | — | — | US | claimed |
| EP-2108648-A1 | Selected CGRP antagonists, method for their manufacture and use as medicines | Boehringer Ingelheim International GmbH (DE) | 2009-10-14 | — | — | EP | claimed |
| EP-1732917-B8 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2009-09-09 | — | — | EP | claimed |
| US-20090176770-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-09 | — | — | US | claimed |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | claimed |
| US-7479488-B2 | Selected CGRP—antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-20 | — | — | US | claimed |
| US-7217702-B2 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2007-05-15 | — | — | US | claimed |
| EP-1740587-A2 | SELECTIVE ANTAGONISTS OF A-2A- ADENOSINE RECEPTORS | Adenosine Therapeutics, LLC (US) | 2007-01-10 | — | — | EP | claimed |
| EP-1732917-A1 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2006-12-20 | — | — | EP | claimed |
| US-20050282831-A1 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2005-12-22 | — | — | US | claimed |
| WO-2005097140-A2 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2005-10-20 | — | — | WO | claimed |
| US-20050234067-A1 | Selected CGRP - antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | claimed |
| WO-2005092880-A1 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282831-A1 | Selective antagonists of A2A adenosine receptors | ADORA2A, ADORA2B, ADORA3 | SLC6A12 2040/4885SLC6A11 1177/4885SLC6A13 926/4885 |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | SLC6A12 4872/4885SLC6A11 4184/4885SLC6A13 4386/4885 |
| US-20090176770-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | SLC6A12 1278/4885SLC6A11 297/4885SLC6A13 545/4885 |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | ADORA2A, PDE4A, PDE4B | SLC6A12 2628/4885SLC6A11 3048/4885SLC6A13 3229/4885 |
| US-20050234067-A1 | Selected CGRP - antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | SLC6A12 1191/4885SLC6A11 294/4885SLC6A13 544/4885 |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | SLC6A12 2769/4885SLC6A11 2533/4885SLC6A13 2837/4885 |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | SLC6A12 4872/4885SLC6A11 4184/4885SLC6A13 4386/4885 |
| US-20100249114-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | SLC6A12 1278/4885SLC6A11 297/4885SLC6A13 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.